Key Publications

Liver Quantification and Liver Fat

Wei H, Decker K, Nguyen H, Cao S, Tsai TY, Dianne Guy C, Bashir M, Liu C. Imaging diamagnetic susceptibility of collagen in hepatic fibrosis using susceptibility tensor imaging. Magn Reson Med. 2020 Apr;83(4):1322-1330.

Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology. 2020 Aug 8:S0016-5085(20)35018-6.

Harrison SA, Rossi SJ, Paredes AH, Trotter JF, Bashir MR, Guy CD, Banerjee R, Jaros MJ, Owers S, Baxter BA, Ling L, DePaoli AM. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020 Apr;71(4):1198-1212.

Du K, Chitneni SK, Suzuki A, Wang Y, Henao R, Hyun J, Premont RT, Naggie S, Moylan CA, Bashir MR, Abdelmalek MF, Diehl AM. Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression. 2019 Dec 25.

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomized, placebo-controlled, phase 2 trial. Lancet 2019 Nov 30;394(10213):2012-2024.

Bashir MR, Wolfson T, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, Van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB. Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2019 May;49(5):1456-1466.

Click here for Additional Publications for Liver Quantification and Liver Fat

Liver Cancer

Vietti Violi N, Lewis S, Liao J, Hulkower M, Hernandez-Meza G, Smith K, Babb JS, Chin X, Song J, Said D, Kihira S, Sirlin CB, Reeder SB, Bashir MR, Fowler KF, Ferket BS, Sigel K, Taouli B. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. Eur Radiol. 2020 Jun 25.

Shropshire E, Mamidipalli A, Wolfson T, Allen BC, Jaffe TA, Igarashi S, Higaki A, Tanabe M, Gamst A, Sirlin CB, Bashir MR. LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations:  an exploratory study. Abdom Radiol (NY). 2020 Feb 12.

Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, Ronald J, Commander L, Hertel J, Luo S, Bashir MR, Burke LMB. The LI-RADS version 2018 MRI treatment response algorithm:  Evaluation of ablated hepatocellular carcinoma. Radiology 2020 Feb;294(2):320-326.

Yamashita R, Mittendorf A, Zhu Z, Fowler KJ, Santillan CS, Sirlin CS, Bashir MR, Do RKG.  Deep convolutional neural network applied to the Liver Imaging Reporting and Data System (LI-RADS) version 2014 category classification:  A pilot study. Abdom Radiol (NY). 2020 Jan;45(1):24-35.

Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Santillan C, Sirlin CB, Mitchell DG, Cerny M, Tang A, Elsayes KM, Kamaya A, Kono Y, Arora SS. An update for LI-RADS:  Version 2018.  Why so soon after version 2017? J Magn Reson Imaging. 2019 Dec;50(6):1990-1991.

Elsayes KM, Fowler KJ, Chernyak V, Elmohr MM, Kielar AZ, Hecht E, Bashir MR, Furlan A, Sirlin CB. User and system pitfalls in liver imaging with LI-RADS. J Magn Reson Imaging. 2019 Dec;50(6):1673-1686.

Wei H, Decker K, Nguyen H, Cao S, Tsai TY, Dianne Guy C, Bashir M, Liu C. Imaging diamagnetic susceptibility of collagen in hepatic fibrosis using susceptibility tensor imaging. Magn Reson Med. 2019 Oct 21.

Click here for Additional Publications for Liver Cancer

Contrast Agents

Nguyen KL, Yoshida T, Kathuria-Prakash N, Zaki IH, Varallyay CG, Semple SI, Saouaf R, Rigsby CK, Stoumpos S, Whitehead KK, Griffin LM, Saloner D, Hope MD, Prince MR, Fogel MA, Schiebler ML, Roditi GH, Radjenovic A, Newby DE, Neuwelt EA, Bashir MR, Hu P, Finn JP. Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI. Radiology. 2019 Dec;293(3):554-564.

Vernuccio F, Cannella R, Meyer M, Choudhoury KR, Gonzales F, Schwartz FR, Gupta RT, Bashir MR, Furlan A, Marin D. LI-RADS: Diagnostic performance of hepatobiliary phase hypointensity and major imaging features of LR-3 and LR-4 lesions measuring 10-19 mm with arterial phase hyperenhancement. AJR Am J Roentgenol. 2019 Aug;213(2):W57-W65

Vietti Violi N, Lewis S, Liao J, Hulkower M, Hernandez-Meza G, Smith K, Babb JS, Chin X, Song J, Said D, Kihira S, Sirlin CB, Reeder SB, Bashir MR, Fowler KF, Ferket BS, Sigel K, Taouli B. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. Eur Radiol. 2020 Jun 25.

Click here for Additional Publications for Contrast Agents